NVO Gets Positive CHMP Opinion in EU for Ozempic Expanded Use in CKD

Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the label expansion of Ozempic (semaglutide) to treat patients with type II diabetes (T2D) and chronic kidney disease (CKD) in the EU. Subject to approval, the drug will be indicated as an adjunct to the standard of care for the prevention of the progression of renal impairment in T2D and CKD patients. A final decision from EMA is expe ...